Drugs for Mastocytosis, Cutaneous (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 103)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Imatinib Mesylate |
|
Phase 4 |
|
220127-57-1 |
|
Synonyms:
GLEEVEC
GLIVEC
IMATINIB MESILATE
IMATINIB MESYLATE
|
IMATINIB METHANESULFONATE
STI571
STI-571
|
|
2 |
|
Cladribine |
Approved, Investigational |
Phase 3 |
|
4291-63-8 |
20279 |
Synonyms:
(2R,3S,5R)-5-(6-Amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
2-CdA
2-Chloro-2'-deoxyadenosine
2-Chloro-2'-deoxy-b-adenosine
2-Chloro-2'-deoxy-beta-adenosine
2-Chloro-2'-deoxy-β-adenosine
2-Chloro-6-amino-9-(2-deoxy-b-D-erythro-pentofuranosyl)purine
2-Chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine
2-Chloro-6-amino-9-(2-deoxy-β-D-erythro-pentofuranosyl)purine
2-Chlorodeoxyadenosine
2-Chloro-deoxyadenosine
2ClAdo
2'-Deoxy-2-chloroadenosine
Chlorodeoxyadenosine
|
CLADARIBINE
Cladribina
CLADRIBINE
Cladribinum
CldAdo
LEUSTAT
Leustatin
LITAK
Mavenclad
Mylinax
NSC-05014
NSC-105014
NSC-105014-F
RWJ-26251
|
|
3 |
|
Denosumab |
Approved |
Phase 3 |
|
615258-40-7 |
|
Synonyms:
AMG-162
Denosumab
PROLIA
PROLIA, RANMARK XGEVA
|
PROLIA, XGEVA
TK006
TK-006
XGEVA
|
|
4 |
|
Hydroxychloroquine |
Approved |
Phase 2, Phase 3 |
|
118-42-3 |
3652 |
Synonyms:
(+-)-Hydroxychloroquine
(±)-HYDROXYCHLOROQUINE
2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
7-Chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(N-ethyl-N-b-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-[4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino]quinoline
7-Chloro-4-[4-(N-ethyl-N-b-hydroxyethylamino)-1-methylbutylamino]quinoline
7-Chloro-4-[4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline
7-Chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
Axemal
DOLQUINE
Dolquine®|Plaquenil®
Ercoquin
Gen-Hydroxychloroquine 200mg Tablets
HCQ
Hidroxicloroquina
|
Hidroxicloroquina [inn-spanish]
Hydroxychlorochin
Hydroxychloroguine
HYDROXYCHLOROQUINE
Hydroxychloroquine sulfate
Hydroxychloroquine sulfate (1:1) salt
Hydroxychloroquinum
Hydroxychloroquinum [inn-latin]
Idrossiclorochina [dcit]
NSC4375
Oxichlorochine
Oxichlorochinum
Oxichloroquine
Oxychlorochin
Oxychloroquine
Plaquenil
Polirreumin
Quensyl
|
|
5 |
|
2-chloro-3'-deoxyadenosine |
|
Phase 3 |
|
|
14485373 |
6 |
|
interferons |
|
Phase 3 |
|
|
|
7 |
|
Interferon-alpha |
|
Phase 3 |
|
|
|
8 |
|
Leukotriene Antagonists |
|
Phase 3 |
|
|
|
9 |
|
Proton Pump Inhibitors |
|
Phase 3 |
|
|
|
10 |
|
Antidepressive Agents |
|
Phase 3 |
|
|
|
11 |
|
Histamine H1 Antagonists |
|
Phase 3 |
|
|
|
12 |
|
Histamine Antagonists |
|
Phase 3 |
|
|
|
13 |
|
Cromolyn Sodium |
|
Phase 3 |
|
|
|
Synonyms:
AEROCROM
ALLERCROM
ASPIRE
BROL-EZE
CATACROM
CLARITEYES
CROLOM
CROMOGEN
CROMOGEN E-BREATHE
CROMOGLICATE SODIUM
CROMOGLYCIC ACID
CROMOLUX
CROMOLYN
CROMOLYN DISODIUM SALT
CROMOLYN SODIUM
CROMOPTIC
CROMOSOL
CROMOSOL OPTHA
CUSILYN
DOMINION PHARMA HAYFEVER
EYE-CROM
FPL-670
GASTROCROM
|
GLYCAVENT
GPPE SYNCRONER INHA
HAY-CROM
INTAL
INTAL 5
LOMUDAL
LOMUSOL
MURINE
NALCROM
NASALCROM
NSC-109500
OPTICROM
OPTICROM AQ
RESISTON ONE
RESISTON TREATMENT PACK
RYNACROM
RYNACROM ALLERGY
RYNACROM CO
SODIUM CROMOGLICATE
STERI-NEB CROMOGEN
VIVICROM
VIVIDRIN
VIZ-ON
|
|
14 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
15 |
|
Antirheumatic Agents |
|
Phase 2, Phase 3 |
|
|
|
16 |
|
Anti-Infective Agents |
|
Phase 2, Phase 3 |
|
|
|
17 |
|
Antiprotozoal Agents |
|
Phase 2, Phase 3 |
|
|
|
18 |
|
Antiparasitic Agents |
|
Phase 2, Phase 3 |
|
|
|
19 |
|
Antimalarials |
|
Phase 2, Phase 3 |
|
|
|
20 |
|
Dasatinib |
Approved, Investigational |
Phase 2 |
|
302962-49-8 |
3062316 |
Synonyms:
(18F)-N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Anh. dasatinib
Anhydrous dasatinib
BMS 345825
BMS 345825|BMS 354825|BMS 35482513|Sprycel®
BMS 354825
BMS 35482513
BMS Dasatinib
BMS-354825
BMS-354825 HYDRATE
BMS-354825-03
|
DASATINIB
Dasatinib (anh.)
dasatinib (anhydrous)
DASATINIB ANHYDROUS
DASATINIB HYDRATE
DASATINIB MONOHYDRATE
Dasatinibum
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Sprycel
|
|
21 |
|
Everolimus |
Approved |
Phase 2 |
|
159351-69-6 |
70789204 6442177 |
Synonyms:
001, RAD
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-HYDROXYETHYL)RAPAMYCIN
Afinitor
AFINITOR DISPERZ
Afinitor®|Certican®|RAD-001|RAD001|rapamycin, 42-O-(2-hydroxyethyl)-|Zortress®
Certican
EVEROLIMUS
évérolimus
RAD 001
|
RAD 666
RAD, SDZ
RAD001
RAD-001
RAD-666
SDZ RAD
SDZ-RAD
VOTUBIA
ZORTRESS
|
|
22 |
|
Denileukin diftitox |
Approved, Investigational |
Phase 2 |
|
173146-27-5 |
|
Synonyms:
DAB(SUB 389)IL2
DAB389 IL2
DAB389IL2
DAB-389IL2
Denileukin
DENILEUKIN DIFTITOX
DIPHTHERIA TOXIN PRECURSOR
DT
|
E7272
E7777
Interleukin-2/diptheria toxin fusion protein
LY335348
LY-335348
NAD(+--DIPHTHAMIDE ADP- RIBOSYLTRANSFERASE)
ONTAK
|
|
23 |
|
Midostaurin |
Approved, Investigational |
Phase 2 |
|
120685-11-2 |
9829523 |
Synonyms:
4'-N-BENZOYLSTAUROSPORINE
BENZOYLSTAUROSPORINE
CGP 41231
CGP 41231|CGP 41251|N-benzoylstaurosporine|PKC412|Rydapt®
CGP 41251
CGP-41251
MIDOSTAURIN
|
N-BENZOYLSTAUROSPORINE
NVP-PKC412
PKC 412
PKC412
PKC-412
RYDAPT
|
|
24 |
|
Thalidomide |
Approved, Investigational, Withdrawn |
Phase 2 |
|
50-35-1 |
5426 |
Synonyms:
(+-)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(+-)-THALIDOMIDE
(±)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(±)-THALIDOMIDE
1,3-DIOXO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE
2,6-DIOXO-3-PHTHALIMIDOPIPERIDINE
3-PHTHALIMIDOGLUTARIMIDE
Algosediv
ALPHA-(N-PHTHALIMIDO)GLUTARIMIDE
ALPHA-N-PHTHALYLGLUTARAMIDE
alpha-Phthalimidoglutarimide
Asidon 3
Asmadion
Asmaval
Bonbrain
Bonbrrin
Calmore
Calmorex
Celgene brand OF thalidomide
Contergan
Corronarobetin
Distaval
Distaxal
Distoval
Ectiluran
Enterosediv
Gastrinide
Glupan
Glutanon
Grippex
Hippuzon
Imida-Lab
Imidan
Imidene
Isomin
K-17
Kedavon
Kevadon
Lulamin
N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
Neaufatin
Neo
Neosedyn
Neosydyn
Nerosedyn
Neufatin
Neurodyn
Neurosedin
Neurosedym
Neurosedyn
Nevrodyn
Nibrol
Noctosediv
Noxodyn
|
N-Phthalimidoglutamic acid imide
N-Phthaloylglutamimide
N-Phthalylglutamic acid imide
N-PHTHALYL-GLUTAMINSAEURE-IMID
NSC-527179
NSC-66847
Pangul
Pantosediv
Poly-Giron
Polygripan
Predni-Sediv
Pro-ban M
Profarmil
Psycholiquid
Psychotablets
Quetimid
Quietoplex
Sandormin
Sedalis
Sedalis sedi-lab
Sedimide
Sedin
Sedisperil
Sedoval
Shin-naito S
Shinnibrol
Sleepan
Slipro
Softenil
Softenon
Talargan
TALIDEX
TALIDOMIDA
Talimol
Talismol
Telagan
Telargan
Telargean
Tensival
Thaled
Thalidomide
THALIDOMIDUM
Thalidomine usp26
Thalin
Thalinette
Thalomid
Theophilcholine
Valgis
Valgraine
Yodomin
Α-(N-PHTHALIMIDO)GLUTARIMIDE
Α-N-PHTHALYLGLUTARAMIDE
Α-PHTHALIMIDOGLUTARIMIDE
|
|
25 |
|
Fludarabine |
Approved |
Phase 2 |
|
75607-67-9, 21679-14-1 |
30751 657237 |
Synonyms:
2-F-ARAA
2-F-Ara-A|CCRIS 3382|F-Ara-A|Fludara®
2F-Ara-AMP
2-fluoro ARA-A
2-Fluoroadenine arabinoside 5'-monophosphate
2-Fluoroadenine arabinoside 5'-monophosphoric acid
2-Fluoro-ara AMP
2-FLUORO-ARA-A
9 beta-D-Arabinofuranosyl-2-fluoroadenine monophosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-Β-arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-Β-arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
|
9-Β-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-Β-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-Β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-Β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
Beneflur
FAMP
FaraAMP
F-Ara-AMP
Fludara
Fludarabina
FLUDARABINE
Fludarabine 5'-monophosphate
Fludarabine 5'-monophosphoric acid
Fludarabine monophosphate
Fludarabine monophosphoric acid
Fludarabine phosphate
Fludarabine phosphoric acid
Fludarabinum
Fludura
Fluoro-ara-AMP
NSC-312887
NSC-328002
OFORTA
|
|
26 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
27 |
|
Brentuximab vedotin |
Approved, Investigational |
Phase 2 |
|
914088-09-8 |
|
Synonyms:
124490327
ADCETRIS
Adcetris®|anti-CD30 ADC SGN-35|SGN 35
Brentuximab
BRENTUXIMAB VEDOTIN
Brentuximab vedotin brentuximab
|
Brentuximab vedotina
CAC10-VCMMAE
Moab, chimeric, SGN-30, to CD30 antigen
Monoclonal antibody SGN-30
SGN-35
|
|
28 |
|
Mycophenolic acid |
Approved, Investigational |
Phase 1, Phase 2 |
|
24280-93-1 |
446541 |
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
68618
Acid, mycophenolic
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
Cellcept
ERL080
ERL-080
ERL-080|Myfortic® (mycophenolate sodium)
Melbex
Micofenolico acido
Mofetil hydrochloride, mycophenolate
Mofetil, mycophenolate
|
Mycophenoic acid
Mycophenolate
Mycophenolate mofetil
Mycophenolate mofetil hydrochloride
Mycophenolate sodium
Mycophenolate, sodium
MYCOPHENOLIC ACID
Mycophenolic acid morpholinoethyl ester
Mycophenolsaeure
Mycophenolsäure
Myfortic
NSC-129185
RS-61443 [AS MOFETIL]
Sodium mycophenolate
|
|
29 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 1, Phase 2 |
|
22916-47-8 |
4189 |
Synonyms:
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
Brentan
CONOFITE
Dactarin
DERMAZOLE
DUMICOAT
Esteve brand OF miconazole
florid(nitrate)|Monistat®|R-14889
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
LORAMYC
MCZ
MICATIN
|
Miconasil nitrate
Miconazol
Miconazole
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazolum
Monistat
MONISTAT-3
MONISTAT-DERM
Nitrate, miconasil
Nitrate, miconazole
NSC-170986
Oravig
VUSION
|
|
30 |
|
Clotrimazole |
Approved, Vet_approved |
Phase 1, Phase 2 |
|
23593-75-1 |
2812 |
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-Chloro-a,a-diphenylbenzyl)imidazole
1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole
1-(O-Chlorotrityl)imidazole
1-(O-Chloro-α,α-diphenylbenzyl)imidazole
1-(Α-(2-chlorophenyl)benzhydryl)imidazole
ABTRIM
ACTAVALL
Bay b 5097
BAY-5097
Bayer brand 1 OF clotrimazole
Bayer brand 2 OF clotrimazole
CANDIDEN
Canesten
Canesten 1-day cream combi-pak
Canesten 1-day therapy
Canesten 3-day therapy
Canesten 6-day therapy
CANESTEN AF
Canesten combi-pak 1-day therapy
Canesten combi-pak 3-day therapy
Canesten cream
CANESTEN CRM COMBI
CANESTEN INTERNAL
Canesten solution
CANESTEN VC
Canesten®|Lotrimin®
Canestine
Chlotrimazole
Clotrimaderm
Clotrimaderm cream
Clotrimazol
CLOTRIMAZOLE
Clotrimazole schering brand
Clotrimazolum
Desamix F
Empecid
FB b 5097
Fem care
FemCare
FUNGEDERM
GNF-PF-3499
Gyne lotrimin
Gyne-lotrimin
Gyne-lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-lotrimin combination pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
|
Gynix
Kanesten
Klotrimazole
Lopac-C-6019
Lotrimax
Lotrimin
LOTRIMIN (TN)
Lotrimin af
Lotrimin af cream
Lotrimin af jock-itch cream
Lotrimin af lotion
Lotrimin af solution
Lotrimin cream
Lotrimin lotion
Lotrimin solution
Lotrisone
MASNODERM
mono-Baycuten
Monobaycuten
Mycelax
Mycelex
MYCELEX (TN)
Mycelex 7
Mycelex cream
Mycelex g
Mycelex otc
Mycelex solution
Mycelex troches
Mycelex twin pack
Mycelex: mycosporinrimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-g
MYCIL GOLD
Myclo cream
Myclo solution
Myclo spray solution
Myclo-gyne
Mycosporin
Mykosporin
Neo-zol cream
NSC-257473
Otomax
Pedisafe
Prestwick_120
PRIVACOM
Rimazole
Schering brand OF clotrimazole
Tibatin
Trimysten
Trivagizole 3
Veltrim
|
|
31 |
|
Alemtuzumab |
Approved, Investigational |
Phase 2 |
|
216503-57-0 |
|
Synonyms:
ALEMTUZUMAB
ALEMTUZUMAB (GENETICAL RECOMBINATION)
CAMPATH
campath 1H|Campath®|campath-1H|Lemtrada®
CAMPATH MABCAMPATH
CAMPATH MABCAMPATH, LEMTRADA
|
CAMPATH-1H
GZ402673
GZ-402673
LDP-03
LEMTRADA
MABCAMPATH
|
|
32 |
|
Iron |
Approved |
Phase 2 |
|
7439-89-6 |
29936 |
Synonyms:
Carbonyl iron
Eisen
Electrolytic iron
Fe
FE (III) ion
Fe(3+)
Fe(III)
fer
Ferric ion
Ferric iron
Ferrum
|
Ferrum metallicum
Hierro
Iron powder
Iron(3+)
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (fe(3+))
Iron, reduced
Reduced iron
|
|
33 |
|
Deferasirox |
Approved, Investigational |
Phase 2 |
|
201530-41-8 |
214348 5493381 |
Synonyms:
4-(3,5-Bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid
DEFERASIROX
Deferasiroxum
Deferasiroxum [inn-latin]
Exjade
ICL 670
ICL 670a
|
ICL670
ICL-670
ICL670a
ICL-670a
Jadenu
JADENU SPRINKLE
|
|
34 |
|
Histamine |
Approved, Investigational |
Phase 2 |
|
51-45-6 |
774 |
Synonyms:
1H-Imidazole-4-ethanamine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
|
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Eramin
Ergamine
Ergotidine
Histamine
HSM
Imidazole-4-ethylamine
NSC-33792
Β-imidazolyl-4-ethylamine
|
|
35 |
|
Diphenhydramine |
Approved, Investigational |
Phase 2 |
|
147-24-0, 58-73-1 |
3100 |
Synonyms:
[2-(DIPHENYLMETHOXY)ETHYL]DIMETHYLAMINE
2-(Benzhydryloxy)-N,N-dimethylethylamine
2-Diphenylmethoxy-N,N-demthylethanamine
2-Diphenylmethoxy-N,N-dimethylethylamine
a-(2-Dimethylaminoethoxy)diphenylmethane
Alledryl
Allerdryl
Allergan
Allergina
alpha-(2-Dimethylaminoethoxy)diphenylmethane
ANTITUSSIVE
b-Dimethylaminoethanol diphenylmethyl ether
b-Dimethylaminoethyl benzhydryl ether
BELDIN
BELIX
Benadryl
BENADRYL PRESERVATIVE FREE
Benadryl®|benzhydramine|dimehydrinate
Bendylate
Benhydramin
Benylin
Benzantin
Benzhydramine
beta-Dimethylaminoethanol diphenylmethyl ether
beta-Dimethylaminoethyl benzhydryl ether
CALADRYL
Citrate, diphenhydramine
COLTEX
DIBENIL
Difenhidramina
Difenhydramine
Dimedrol
Dimedrolum
DIMEHYDRINATE
Dimethylamine benzhydryl ester
Diphamine
Diphantine
|
DIPHEN
DIPHENHYDRAMINE
Diphenhydramine citrate
Diphenhydramine citrate (1:1)
DIPHENHYDRAMINE HCL
Diphenhydramine hydrochloride
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE
Diphenhydraminum
Diphenylhydramin
Diphenylhydramine
Dobacen
Dormin
DREEMON
DYTUSS
FEDRIL
GPPE COUGH EXPECT PAED
GPPE ORAL SOLN
HISTERGAN
HYDRAMINE
Hydrochloride, diphenhydramine
MEDINEX
N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine
NIGHTCALM
NSC-33299
NYTOL
NYTOL ONE-A-NIGHT
O-Benzhydryldimethylaminoethanol
PAXIDORM
Restamin
SILPHEN
SLEEPIA
SYNTEDRIL
TIXYLIX CATARRH
VICKS FORMULA 44
Α-(2-dimethylaminoethoxy)diphenylmethane
Β-dimethylaminoethanol diphenylmethyl ether
Β-dimethylaminoethyl benzhydryl ether
|
|
36 |
|
Promethazine |
Approved, Investigational |
Phase 2 |
|
60-87-7 |
4927 |
Synonyms:
(2-Dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine
10-(2-Dimethylaminopropyl)phenothiazine
10-[2-(Dimethylamino)propyl]phenothiazine
Atosil
Diphergan
Diprazin
Hydrochloride, promethazine
Isopromethazine
Lilly 1516
N-(2'-Dimethylamino-2'-methyl)ethylphenothiazine
N,N,alpha-Trimethyl-10H-phenothiazine-10-ethanamine
N,N,a-Trimethyl-10H-phenothiazine-10-ethanamine
N,N,Α-trimethyl-10H-phenothiazine-10-ethanamine
NSC-30321
Phenargan
Phenergan
Phenergan®|Sominex®
Phensedyl
Pipolfen
Pipolphen
Proazaimine
Proazamine
|
Promazinamide
Promet
Prometazin
Prometazina
Prometazine
PROMETHACON
Promethazin
PROMETHAZINE
Promethazine hydrochloride
Promethazinum
PROMETHEGAN
Promethiazine
Promezathine
Prothazin
Prothazine
Pyrethia
Remsed
RP-3277
Rumergan
SOMINEX
ZIPAN-25
ZIPAN-50
|
|
37 |
|
Azacitidine |
Approved, Investigational |
Phase 1, Phase 2 |
|
320-67-2 |
9444 |
Synonyms:
4-Amino-1-b-D-ribofuranosyl-S-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-S-triazin-2(1H)-one
4-Amino-1-β-D-ribofuranosyl-S-triazin-2(1H)-one
5 Azacytidine
5 AZC
5-AZAC
5-azacytidine
Azacitidina
|
Azacitidine
Azacitidinum
Azacytidine
LADAKAMYCIN
NSC-102816
Pharmion brand OF azacitidine
U-18496
Vidaza
|
|
38 |
|
Sunitinib |
Approved, Investigational |
Phase 2 |
|
557795-19-4 |
5329102 |
Synonyms:
5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
SU011248
SU-011248
SU11248
SU-11248
|
SU11248|Sutent®
SUNITINIB
Sunitinib malate
Sunitinibum
Sutent
|
|
39 |
|
D-Tyrosine |
Approved, Experimental, Investigational, Nutraceutical |
Phase 2 |
|
133585-56-5, 60-18-4, 556-02-5 |
1153 6057 |
Synonyms:
(-)-a-Amino-p-hydroxyhydrocinnamate
(-)-a-Amino-p-hydroxyhydrocinnamic acid
(-)-alpha-Amino-p-hydroxyhydrocinnamate
(-)-alpha-Amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamate
(−)-α-amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamic acid
(2S)-2-Amino-3-(4-hydroxyphenyl)propanoate
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-AMINO-3-(4-HYDROXYPHENYL)PROPIONIC ACID
(2S)-2-AZANYL-3-(4-HYDROXYPHENYL)PROPANOIC ACID
(R)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(R)-3-(p-Hydroxyphenyl)alanine
(S)-(-)-Tyrosine
(S)-2-Amino-3-(p-hydroxyphenyl)propionate
(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(S)-3-(p-Hydroxyphenyl)alanine
(S)-a-Amino-4-hydroxybenzenepropanoate
(S)-a-Amino-4-hydroxy-benzenepropanoate
(S)-a-Amino-4-hydroxybenzenepropanoic acid
(S)-a-Amino-4-hydroxy-benzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoate
(S)-alpha-Amino-4-hydroxy-benzenepropanoate
(S)-alpha-amino-4-Hydroxybenzenepropanoic acid
(S)-alpha-Amino-4-hydroxy-benzenepropanoic acid
(S)-Tyrosine
(S)-Α-amino-4-hydroxybenzenepropanoate
(S)-α-amino-4-hydroxybenzenepropanoic acid
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid
2-Amino-3-(4-hydroxyphenyl)propanoate
|
2-Amino-3-(4-hydroxyphenyl)propanoic acid
2-Amino-3-(p-hydroxyphenyl)propionate
2-Amino-3-(p-hydroxyphenyl)propionic acid
3-(4-Hydroxyphenyl)-L-alanine
3-(p-Hydroxyphenyl)alanine
4-hydroxy-L-phenylalanine
6-Hydroxysandoricin
Benzenepropanoate
Benzenepropanoic acid
D-Tyr
D-Tyrosin
FEMA NO. 3736
L Tyrosine
LEVODOPA IMPURITY, L-TYROSINE-
LEVODOPA RELATED COMPOUND L-TYROSINE
L-p-Tyrosine
L-Tyrosin
L-tyrosine
Methyl 2-[5,11-bis(acetyloxy)-13-(furan-3-yl)-16-hydroxy-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.0¹,¹².0³,⁸]heptadecan-7-yl]-2-hydroxyacetic acid
NSC-82624
Para tyrosine
Para-tyrosine
p-Tyrosine
Tirosina
Tyr
Tyrosin
Tyrosine
Tyrosine, L isomer
Tyrosine, L-isomer
Tyrosinum
Y
|
|
40 |
|
Obatoclax |
Investigational |
Phase 2 |
|
803712-67-6 |
46930997 |
Synonyms:
GX15-070
GX-15-070|GX15-070|obatoclax mesylate|SB16622
|
|
|
41 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
42 |
|
Immunosuppressive Agents |
|
Phase 1, Phase 2 |
|
|
|
43 |
|
Interleukin-2 |
|
Phase 2 |
|
|
|
44 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
45 |
|
Immunoconjugates |
|
Phase 2 |
|
|
|
46 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
47 |
|
Calcineurin Inhibitors |
|
Phase 1, Phase 2 |
|
|
|
48 |
|
Cyclosporins |
|
Phase 1, Phase 2 |
|
|
|
49 |
|
Antifungal Agents |
|
Phase 1, Phase 2 |
|
|
|
50 |
|
Antitubercular Agents |
|
Phase 1, Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 61)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Imatinib Mesylate Therapy in Systemic Mastocytosis Patients Lacking KIT Mutations |
Completed |
NCT01297777 |
Phase 4 |
Imatinib Mesylate |
2 |
Subcutaneous Cladribine Plus Pegylated Interpheron Alfa-2a in Advanced Systemic Mastocytosis With D816V and Other Exon 17 KIT Mutations. |
Unknown status |
NCT01602939 |
Phase 2, Phase 3 |
Cladribine and pegylated interpheron alpha-2a |
3 |
Randomized, Placebo-controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib at 6 mg/kg/Day to Placebo in Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap |
Completed |
NCT00814073 |
Phase 3 |
Masitinib;Placebo |
4 |
Phase 3 Study to Compare Oral Masitinib to Placebo in Treatment of Patients With Smouldering or Indolent Severe Systemic Mastocytosis, Unresponsive to Optimal Symptomatic Treatment |
Recruiting |
NCT04333108 |
Phase 3 |
Masitinib |
5 |
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis |
Recruiting |
NCT04910685 |
Phase 2, Phase 3 |
BLU-263;Placebo |
6 |
Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis |
Active, not recruiting |
NCT03401060 |
Phase 3 |
Denosumab;Placebo |
7 |
Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients: Proof of Concept Study |
Not yet recruiting |
NCT05084872 |
Phase 2, Phase 3 |
Hydroxychloroquine |
8 |
Phase II Single Arm Open Pilot Study to Demonstrate the Efficacy of Midostaurin in Symptom Improvement and Decrease of Mast Cell Burden in Patients With Indolent or Smoldering Systemic Mastocytosis. |
Unknown status |
NCT01920204 |
Phase 2 |
Midostaurin, |
9 |
Multicenter, Open-Label, Single Arm Phase II Clinical Trial of Dasatinib in the Treatment of Systemic Mastocytosis |
Unknown status |
NCT00979160 |
Phase 2 |
Dasatinib |
10 |
Efficacy and Safety of TF002 in Cutaneous Mastocytosis |
Completed |
NCT00457288 |
Phase 2 |
TF 002 |
11 |
Evaluation of RAD001 as Therapy for Patients With Systemic Mastocytosis |
Completed |
NCT00449748 |
Phase 2 |
RAD001 (Everolimus) |
12 |
ONTAK (Denileukin Diftitox) in Patients With Systemic Mastocytosis |
Completed |
NCT00493129 |
Phase 2 |
Ontak (Denileukin Diftitox) |
13 |
A Single Arm, Phase II, Open-Label Study to Determine the Efficacy of 100mg Twice Daily Oral Dosing of Midostaurin Administered to Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia +/- an Associated Hematological Clonal Non-Mast Cell Lineage Disease |
Completed |
NCT00782067 |
Phase 2 |
Midostaurin (PKC412) |
14 |
Phase II Study of Thalidomide in Mastocytosis |
Completed |
NCT00769587 |
Phase 2 |
thalidomide |
15 |
A Phase II Clinical Trial of 17-(Allylamino)-17- Demethoxygeldanamycin (17-AAG, NSC 330507 and EPL Diluent, NSC 704057) in Adults With Systemic Mastocytosis |
Completed |
NCT00132015 |
Phase 2 |
tanespimycin |
16 |
Low Intensity Preparative Regimen Followed by HLA-Matched, Mobilized Peripheral Blood Stem Cell Transplantation for Systemic Mastocytosis |
Completed |
NCT00006413 |
Phase 2 |
|
17 |
Randomized, Double-blind, Placebo-controlled, Crossover Design, Efficacy and Safety Study With PA101 in Patients With Indolent Systemic Mastocytosis |
Completed |
NCT02478957 |
Phase 2 |
PA101;Placebo |
18 |
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes |
Completed |
NCT00171912 |
Phase 2 |
imatinib mesylate |
19 |
A Phase IA/II Multicenter, Dose-escalation Study of Oral AMN107 on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-resistant/Intolerant CML in Chronic or Accelerated Phase or Blast Crisis, Relapsed/Refractory Ph+ ALL, and Other Hematologic Malignancies. |
Completed |
NCT00109707 |
Phase 1, Phase 2 |
Nilotinib |
20 |
A Single Arm, Phase 2, Open-Label Study to Determine the Efficacy of Twice Daily Oral Dosing of PKC412 <Midostaurin> Administered to Patients With Aggressive Systemic Mastocytosis (ASM) and Mast Cell Leukemia (MCL) |
Completed |
NCT00233454 |
Phase 2 |
Midostaurin |
21 |
A Study of Brentuximab Vedotin (SGN-35) in CD30-Positive Systemic Mastocytosis With or Without an Associated Hematological Clonal Non-Mast Cell Lineage Disease (AHNMD) |
Completed |
NCT01807598 |
Phase 2 |
Brentuximab vedotin |
22 |
Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil |
Completed |
NCT00006251 |
Phase 1, Phase 2 |
fludarabine phosphate;cyclosporine;mycophenolate mofetil |
23 |
Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial |
Completed |
NCT00118352 |
Phase 2 |
fludarabine phosphate;cyclosporine;mycophenolate mofetil |
24 |
Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload |
Completed |
NCT01273766 |
Phase 2 |
deferasirox |
25 |
An Open-Label Pilot Study to Evaluate the Effectiveness and Tolerability of a Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis |
Recruiting |
NCT04846348 |
Phase 2 |
|
26 |
A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of The Safety and Efficacy of CGT9486 in Subjects With Nonadvanced Systemic Mastocytosis |
Recruiting |
NCT05186753 |
Phase 2 |
CGT9486 Tablets;Placebo Tablets |
27 |
A Phase 2 Randomized Double-Blinded Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in Subjects With Indolent Systemic Mastocytosis |
Recruiting |
NCT03770273 |
Phase 2 |
|
28 |
A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis |
Recruiting |
NCT04996875 |
Phase 2 |
CGT9486 tablets |
29 |
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy |
Active, not recruiting |
NCT03731260 |
Phase 2 |
Avapritinib;Placebo |
30 |
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis |
Active, not recruiting |
NCT03580655 |
Phase 2 |
Avapritinib |
31 |
A Phase 1/2, Open-label, 2-arm Study Evaluating BLU-263 as Monotherapy and in Combination With Azacitidine, in Patients With KIT Altered Hematologic Malignancies |
Not yet recruiting |
NCT05609942 |
Phase 1, Phase 2 |
BLU-263;Azacitidine |
32 |
Evaluation of Obatoclax Mesylate as Therapy for Patients With Systemic Mastocytosis |
Terminated |
NCT00918931 |
Phase 2 |
Obatoclax Mesylate |
33 |
GTB-3550 (CD16/IL-15/CD33)Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis |
Terminated |
NCT03214666 |
Phase 1, Phase 2 |
GTB-3550 TriKE® Phase I;GTB-3550 TriKE® Phase II |
34 |
A Phase 2 Study of Ibrutinib in Advanced Systemic Mastocytosis |
Terminated |
NCT02415608 |
Phase 2 |
Ibrutinib |
35 |
A Phase II Study of Sunitinib Malate in Idiopathic Myelofibrosis |
Terminated |
NCT00387426 |
Phase 2 |
sunitinib malate |
36 |
A Phase 2 Study to Evaluate the Anti-Tumor Activity of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies |
Withdrawn |
NCT03739606 |
Phase 2 |
|
37 |
A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients With Advanced Malignancies |
Completed |
NCT02571036 |
Phase 1 |
DCC-2618 |
38 |
A Phase 1, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 in Patients With Indolent Systemic Mastocytosis |
Completed |
NCT02808793 |
Phase 1 |
AK002 |
39 |
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy |
Completed |
NCT00890747 |
Phase 1 |
sunitinib malate |
40 |
A Phase I Study of MK-2206, an AKT Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors or Leukemia |
Completed |
NCT01231919 |
Phase 1 |
Akt inhibitor MK2206 |
41 |
A Phase 1 Trial to Evaluate the Safety of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies |
Recruiting |
NCT04681105 |
Phase 1 |
Acetaminophen;Dexamethasone;Diphenhydramine;Ibuprofen;Ranitidine |
42 |
A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies |
Recruiting |
NCT05362773 |
Phase 1 |
MGD024 |
43 |
A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies |
Active, not recruiting |
NCT02561988 |
Phase 1 |
Avapritinib |
44 |
Evaluation of the Improvement of Pigmented Skin Lesions in Patients With Mastocytosis After Performing 2 Sessions of Pigment Laser : Pilot Study Conducted at a Reference Centre Mastocytoses (LaserMasto) |
Unknown status |
NCT04377828 |
|
|
45 |
Natural History of Urticaria Pigmentosa in Children |
Completed |
NCT00467792 |
|
|
46 |
Cutaneous Mastocytosis in Children: Analysis of Somatic and Germline Mutations |
Completed |
NCT02761473 |
|
|
47 |
Ocular and Palpebral Manifestations of Mastocytosis (MOOMA) |
Completed |
NCT04978740 |
|
|
48 |
Adaptation of the Questionnaire "Regarding Patient's Quality of Life With Mastocytosis" in the French Language |
Completed |
NCT03632811 |
|
|
49 |
An External Control, Observational, Retrospective Study Assessing the Effect of Avapritinib Compared With Best Available Therapy for Patients With Advanced Systemic Mastocytosis |
Completed |
NCT04695431 |
|
|
50 |
Patient-Reported Outcome Questionnaire Development for Symptoms of Systemic Mastocytosis |
Completed |
NCT02380222 |
|
|
|